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ANIMAL MODELS
Experimental Rodent Models of Brainstem Tumors
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Abstract. Despite recent advances in surgical technology, resection is not an option for many brainstem
tumors. Experimental models have played essential roles in examining new approaches to therapy. The objective
of the present study was to generate models by determining coordinates for safe inoculation into the brainstem
of mice and rats, and to establish whether the implantation of heterotopic cells would create reproducible
survival curves. Morbidity and survival studies were used to map stereotactic coordinates allowing successful
inoculation of tumor cells. Survival studies were used to investigate the time course of tumor growth. Tumor
location was examined by light microscopy and magnetic resonance imaging. Mice survived injections of 2 L
of saline at interaural, lateral, and depth coordinates of 2.5, 1.0, and 3.5 mm and 1.5, 1.0, and 3.5 mm.
Rats survived injections at interaural, lateral, and depth coordinates of 2.0, 2.0, and 7.0 mm and 3.0, 0, and
7.0 mm. Median survival of mice challenged with 5  105 EMT6 and 104 B16 tumor cells was 11 and 10
days, respectively. Median survival for rats challenged with 104 9L and F98 cells was 14 and 13 days, respec-
tively. The present study demonstrates a feasible approach to preparing models of brainstem tumors. Limitations
of these models are discussed.
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Brainstem tumors, a heterogeneous set of neo-
plasms, account for 10–20% of lesions arising within
the central nervous system (CNS), and 25% of tumors
arising in the posterior fossa of children.10,13,18 Each
year, 200–300 new cases are diagnosed in the USA.
Low-grade lesions can respond to surgery, chemother-
apy, and radiation. These lesions, which account for
15–25% of cases, have a somewhat optimistic prog-
nosis, with 5-year survival rates of more than 50%.24,26
However, high-grade, diffuse tumors, which account
for the majority of cases, have 2-year survival rates of
10–15%.9,33
Surgery for diffuse lesions has been limited regard-
less of the species because even small iatrogenic le-
sions may yield significant deficits in tissues with little
functional redundancy.4,15,30 Radiation has not pro-
longed survival.12,28 Chemotherapy has not been suc-
cessful, and has been accompanied by organ failures
and lethal infections.14,17,21
Brainstem tumor models are needed to test new
therapies. However, several challenges face develop-
ment of such models. Few tumor cell lines have in-
vasive characteristics of the predominant brainstem
cancers. One might assume that stereotactic implan-
tation techniques that have been widely used in the
brain would directly translate to techniques for the
brainstem. The absence of brainstem models suggests
otherwise. We are unaware of reports describing co-
ordinates for implanting tumor cells in the brainstem.
Cell implantation methods and stereotactic ablation
have been used in mice and rat brains for decades, but
the neurologic sensitivity of the brainstem has limited
work in this area. Schabert and coworkers injected hu-
man medulloblastoma cells into the cisterna magna of
nude rats. They found leptomeningeal growth in the
cisterna magna invading the medulla oblongata, and
tumor growth in the fourth ventricle invading the
pons.27 Their results demonstrate that human tumor
cells can colonize the nude rat brainstem, and suggest
that other heterotopic cells, which may colonize the
cortex, would grow in the pons and medulla. Klopp
and coworkers recently demonstrated an elegant sur-
gical approach to the caudal brainstem in dogs.19 Their
report provides a necessary step in tumor research, that
is, the availability of canine or nonhuman primate
models to bridge the gap between rodent studies and
safety studies in humans.
We hypothesized that tumor cells could be injected
directly into permissive areas of the brainstem paren-
chyma because stereotactic biopsies can be used to
294 Vet Pathol 39:3, 2002Wu, Tyler, Sukay, Rhines, DiMeco, Clatterbuck, Guarnieri, and Carson
Table 1. Stereotactic coordinates for brainstem injections in mice and rats.
Species Stock
Coordinates (mm)*
Interaural Lateral Depth
Mortality
(day 30) Morbidity
Mouse
Mouse
Mouse
Rat
Rat
Rat
BALB/c
BALB/c
C57BL/6
Fischer 344
Fischer 344
Nu/Nu
2.5
2.5
1.5
3.0
2.0
3.0
0
2.0
1.0
0
2.0
0
3.5
3.5
3.5
7.0
7.0
7.0
2/20
1/20
0/20
0/4
0/18
0/4
3/18
2/19
0/20
0/4
0/18
0/4
* Coordinates are based on published stereotactic coordinates of mouse and rat brain anatomy, respectively.11,22
sample mass lesions in the brainstem.30 Intratumoral
drug delivery vehicles could offer therapy to lesions
in surgically inoperable tissues.34 Based on these ob-
servations, the Johns Hopkins Animal Care and Use
Committee approved a study to document implantation
coordinates in mice and rats. The present report de-
scribes the preparation of these models.
Materials and Methods
Experimental design
Sites for placement of cell implants were evaluated by
postoperative monitoring of neurologic symptoms after the
injection of saline at target coordinates. Coordinates are re-
ported based on standard stereotaxic atlases for the rat,22 and
the mouse brain.11 Responses to tumor cell implants were
assessed from survival data and histology.
Animals
Female Fischer 344 rats (180–220) g, female Nu/Nu rats
(150–180 g), female Balb/C mice (18–25 g), and female
C57BL/6 mice (18–25 g) were obtained from Harlan (Indi-
anapolis, IN) and housed according to Johns Hopkins Ani-
mal Care and Use policies and federal guidelines. The num-
bers of animals used in each experiment are given in Tables
1–3.
Cells
The EMT6 breast carcinoma line and B16 melanoma line
were obtained from the DCT Tumor Repository (NCI-Fred-
erick Cancer Research and Development Center, Frederick,
MD). The F98 glioma cells were from R. Goodman (Ohio
State University, Columbus, OH). The 9L gliosarcoma line
was obtained from the Brain Tumor Research Center (Uni-
versity of California, San Francisco, CA). Cells were main-
tained in Dulbecco modified Eagle medium (DMEM) and
10% fetal calf serum supplemented with penicillin–strepto-
mycin and tested by the Gen-Probe Rapid Detection System
(Fisher Scientific, Pittsburgh, PA) to rule out mycoplasma
contamination. Cells were harvested with 0.25% trypsin,
counted, and resuspended in DMEM solution before intra-
cranial implantation.
Chemicals
Tissue Marking Dye, a gift of Triangle Biomedical Sci-
ences (Durham, NC), was used to mark injection sites. Cell
culture supplies including calf serum, DMEM, and trypsin
were from Life Technologies (Rockville, MD).
Surgery
Animals were anesthetized with a stock solution contain-
ing 25 mg/ml ketamine hydrochloride, 2.5 mg/ml xylazine,
and 14.25 % ethyl alcohol in saline; 0.65 ml was used for
rats and 0.20 ml of a dilution of the stock solution was used
for mice. The mouse dilution consisted of two parts saline
and one part stock anesthetic solution. Surgical surfaces were
shaved, washed with 70% ethyl alcohol, and painted with Be-
tadine. With the aid of a Zeiss operating microscope, a 2-mm
burr hole was made at locations described in Table 1.
Animals were moved to a stereotactic head frame after
creation of the burr hole. After placement in the frame, a
10-l 26-gauge Hamilton Gastight 1701 syringe needle was
inserted to a specified depth (as described in Table 1). Over
a period of 4 minutes, 2 l of the dye, saline, or tumor cell
suspension was injected into the brainstem. The needle was
removed. The site was irrigated with 5–10 ml of sterile sa-
line solution. The animal was then removed from the frame
and the wound was closed with 4.0 vicryl or surgical staples.
Animals were monitored immediately after surgery and
daily for the development of signs and symptoms of discom-
fort. Animals demonstrating neurologic signs were euthan-
atized with sodium pentobarbital by intraperitoneal injection
of 0.5 ml of a 50 mg/ml solution, a dose that is equivalent
to 100 mg of drug/kg of animal weight.
Histology
Tissues for histology were prepared from formalin-fixed
sections. Brains with their brainstems and cervical spinal
cords were isolated as a whole and immersed in 4% buffered
formalin. Sections were prepared from paraffin-embedded
specimens. Samples were stained with hematoxylin and eo-
sin (HE) solutions. Tumor volume was estimated by the
method of Cavalieri.6
Magnetic resonance imaging (MRI)
Imaging was performed on an Omega 4.7 Telsa General
Electric spectrophotometer (Milwaukee, WI), equipped with
Acustar actively shielded gradients obtained from General
Electric (Fremont, CA). Before imaging, animals were in-
jected intraperitoneally with 1.0 ml of gadolinium contrast
solution (Magnevist, Berlex Laboratories, Wayne, NJ).
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Fig. 1. Target marking (HE stain) with tissue dye and tumor cell inoculations. Fig. 1A. BALB/c female mouse (20 g).
Injection coordinates, tissue dye: interaural 2.5, lateral 1, depth 3.5 mm. Fig. 1B. Fischer 344 female rat (200 g). Injection
coordinates, tissue dye: interaural 2.0, lateral 0, depth 7.0 mm. Fig. 1C. EMT6 metastatic breast tumor at 10 days generated
by inoculating a BALB/c mouse with 104 cells. Injection coordinates: interaural 2.5, lateral 1, depth 3.5 mm. Fig. 1D.
B16 (melanoma) (dark arrows) at 8 days generated by inoculating a C57BL/6 mouse with 104 cells. Injection coordinates:
interaural 2.5, lateral 0, depth 3.5 mm. Scattered cells containing melanin granules are seen in the choroid plexus (light
arrows).
Statistical analyses
Version 3 of JMP software was used for statistical anal-
yses (SAS Institute Cary, NC). Values of P  0.05 were
considered to be statistically significant.
Results
Injection coordinates in mice and rats
The coordinates for injection of 2 l of saline
through the cerebellum and fourth ventricle into the
mouse and rat brainstem are given in Table 1. Figure
1A and B show injection sites of a tissue marking dye
in a BALB/c mouse and Fischer 344 rat, respectively.
Figure 1C and D show the tumor location in mice
injected with EMT6 and B16 tumor cells. The BALB/
c mouse described in Fig. 1C was euthanatized 10 days
after inoculation with 104 EMT6 tumor cells. Median
survival of mice inoculated with 5  105 EMT6 cells
is 11 days (see below); thus, the tumor volume prob-
ably had not reached a lethal mass. The C57BL/6
mouse shown in Figure 1D was euthanatized 8 days
after inoculation with 104 B16 tumor cells. The median
survival for mice challenged with this dose of cells is
10 days.
Midline injections and injections 1 and 2 mm to
either side of the midline were tolerated in mice and
rats. The animals in Table 1 were observed for at least
30 days; no indication was found of neurologic symp-
toms or mortality in mice or rats injected with saline.
Examination of the data in Table 2 indicates the sen-
sitivity of the brainstem to injections outside the co-
ordinates listed in Table 1. Significant morbidity was
apparent in the immediate postoperative period. The
primary symptom in mice was failure to revive from
the anesthesia. Shallow or irregular respiration was
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Table 2. Brainstem injection coordinates associated
with significant morbidity in rodents.
Species Stock
Coordinates (mm)*
Interaural Lateral Depth
Survival
(day 2)
Mouse
Mouse
Rat
Rat
BALB/c
BALB/c
Fischer 344
Fischer 344
2.5
2.5
2.0
2.0
3.5
2.0
5.0
2.0
3.5
5.5
7.0
9.0
2/5
1/5
1/5
0/5
* Coordinates are based on published stereotactic coordinates of
mouse and rat brain anatomy, respectively.11,22
Fig. 2. Survival depends on the dose of a tumor cell
inoculate. Three Fischer 344 rats in each group were inoc-
ulated with the quantity of F98 cells indicated. Data points
indicate the median ( SD) days of survival. Differences for
survival times for each group are significant, P  0.05.
Table 3. Survival after brainstem inoculation with tumor cells.*
Species Stock Tumor Cell No.
Median
Survival
(days)
Range (n)
(days)
Mouse
Mouse
Rat
Rat
BALB/c
C57BL/6
Fischer 344
Fischer 344
EMT6
B16
9L
F98
5  105
104
104
104
11
10
14
13
6–16 (8)
7–13 (8)
8–20 (32)
7–18 (48)
* Data were collected from one to six control groups of eight animals each in efficacy studies.
followed by death within 8 hours. Rats usually revived
from anesthesia, but were lethargic and failed to drink
or eat. Alternatively, rats exhibited a hemiplegia and
moved in a circle with their nose down in their bed-
ding. These animals were euthanatized.
Tumor cell challenges
Examination of the survival data given in Table 3
indicates the capacity of heterotopic cells to colonize
and proliferate in the brainstem. Inoculations with the
four tumor cell lines proved uniformly lethal. The me-
dian survival time of BALB/c mice injected with 5 
105 of the EMT6 metastatic breast cell line is 11 days.
The median survival time of C57BL/6 mice inoculated
with 104 B16 cells is 10 days. The median survival
time of Fischer rats inoculated with 104 9L or F98 cells
is 14 and 13 days, respectively. These times are no-
tably shorter than those obtained when the same num-
bers of cells are injected into the parietal cortex. For
example, in our laboratory, median survival after cor-
tical injections of 5  105 EMT6 cells in mice and 104
9L cells in rats is about 16 and 20 days, respectively.
Survival is dose dependent. In an experiment with
three Fischer 344 rats per group, survival decreased in
proportion to increasing numbers of F98 cells injected
into the brainstem. Survival was 24  1 days for the
group injected with 103 cells, 14  1 days for animals
injected with 104 cells, and 11  1 days for animals
injected with 105 cells (Fig. 2).
The development of neurologic symptoms in tumor-
challenged animals is consistent with mass effects of
the tumor on centers of respiration and consciousness.
Animals sometime developed mild to moderate limb
paralysis in the 24 hours before expiration. They gen-
erally became lethargic, lapsed into a coma, and died
within 12–24 hours.
Although making histologic comparisons in immer-
sion-fixed tissues is difficult, the appearance of the
brainstem tumors is similar to the histology seen in
cortical inoculations of the same cells. An exception
is that cortical tumors can show evidence of central
necrosis at an autopsy. Figure 3 shows a 9L glioma in
the brainstem of a Fischer 344 rat. The left panel
shows HE-stained tissue at day 10. The right panel, a
gadolinium-enhanced MRI image at day 8 after inoc-
ulation, shows the bulk of the tumor at the site of the
injection, and slight enhancement along the path of the
needle. Little evidence was found of necrosis. The rel-
atively small size of the tumor in the days before death
supports the concept that the mass effects of the tu-
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Fig. 3. Tumor location. Fig. 3A. HE stain of 9L tumor (dark arrows) at day 10 generated by inoculating a Fischer 344
rat with 104 cells on day 0. Fig. 3B. Magnetic resonance image of 9L tumor (light arrows) at day 8 generated by inoculating
a Fischer 344 rat with 104 cells on day 0.
mors are pronounced in tissues having limited func-
tional redundancy; however, further research is needed
to determine the cause of death.
Tumor location and volume
Microscopic examination of the tumor cell–chal-
lenged brains demonstrated that the tumors grew pri-
marily at the site of the inoculation and spread along
the path of the injection. To verify this impression, we
examined tumor location macroscopically and by his-
tology in a group of eight rats inoculated with 104 F98
cells. Tumor volume at autopsy was estimated to be
1.9  0.8 mm3 (range 0.8–3.2 mm3) by the method of
Cavalieri.6 Gross examination revealed the bulk of the
tumor at the site of the injection in the pons below the
floor of the fourth ventricle. Histology revealed addi-
tional substantial tumor growth into the fourth ventri-
cle in five animals. Tumors spread to cerebellar space
in two rats, and to subarachnoid space in one rat. The
extrabrainstem growth in all cases appeared to follow
the path of the injection.
Discussion
Spontaneous tumors of the CNS are rare in most
mouse and rat strains. Tumors can be induced by
chemical carcinogens, although the efficiency of tumor
induction varies greatly.16 Experimental tumors can be
efficiently induced by avian sarcoma virus in Fischer
rats. The mean induction time and frequency of tumors
varied with the age of inoculation.16 Tumors occur
commonly in dogs, but the incidence and natural his-
tory have not been established.19 The present work
demonstrates that four rodent cell lines that efficiently
colonize supratentorial regions of the brain efficiently
grow in the brainstem. The inoculations produce re-
producible survival curves, which is an essential pre-
requisite to efficacy studies. One may reasonably ex-
pect that other neuronal and glial tumor cell lines that
colonized the rodent brain will perform in a similar
manner.
Cell lines used in this study were selected from gen-
eral experience with animal models and efficacy stud-
ies. For example, rat F98 and 9L glioma cell lines have
been used to study tumor cell metabolism in animal
brains,20,31 chemotherapy for brain tumors,3,23 neuro-
toxicity of heavy metals,29 radiation toxicity,32 radia-
tion therapy,1,25 and gene therapy.2,5 The EMT6 breast
tumor line has been used because breast cancer is the
second most common cause of CNS metastases after
lung cancer.8 By the same token, the B16 melanoma
cell line is used because melanoma is the third most
common source of intracranial metastases.7
The surgical approach was selected because of our
laboratory’s experience in using stereotactic frames in
brain tumor models. After a burr hole is created in an
appropriately prepared mouse or rat, the animal can be
rapidly placed in a stereotactic frame for inoculation
by a dorsal approach to the pons via the cerebellum
and fourth ventricle. This is a convenience that facil-
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itates the numbers of animals that must be tested to
obtain statistical validation in toxicity and efficacy
tests. Lateral and ventral approaches, which would be
optimal for surgical resections, were considered but
not explored after a significant effort to map coordi-
nates that allowed safe inoculations through a dorsal
approach. In work to be reported, we have used a sim-
ilar dorsal approach to implant continuous infusion
cannulas into the brainstem of cynomolgus monkeys.
The pattern of tumor growth appears to be similar
to the models of tumor cells in the brain. Tumor cells
expand at the site of injection, leading to mass effects
on adjacent structures. Growth along the injection
track is seen, but in many cases, tumor growth remains
centered about the point of injection. Not surprisingly,
survival is significantly decreased in brainstem-chal-
lenged animals compared to similar tumor cell chal-
lenges in the parietal cortex. One may assume that the
difference is related to the low tolerance of the brain-
stem to tumor mass and edema. However, the limited
sensitivity of immersion-fixed histology prevented fur-
ther assessments with our preparations. Histology with
perfused specimens and specific stains is needed.
The present work demonstrates that inoculations of
1–2 l of saline can be accomplished without apparent
morbidity in normal mice and rats and in immunode-
ficient (Nu/Nu) rats. In studies to be reported, we have
looked for signs of tissue damage resulting from the
inoculation process. Although it is difficult to find the
needle track in tissue sections, microscopic hemor-
rhages and gliosis have been observed near injection
wounds. These results imply that injections of local
therapies, which have shown promise in the brain, may
be applicable to brainstem lesions.
The EMT6 metastatic line and B16 melanoma cells
offer tumor models for metastases to the brainstem.
Although such metastases are regarded as quickly le-
thal, they are rare. None of the cells used in the present
study faithfully mimic invasive characteristics of dif-
fuse gliomas. Availability of the present rodent models
may encourage efforts to develop highly invasive cell
lines characteristic of the more prevalent tumors. Also
note that the typical age range of diffuse pontine gli-
omas is 2–9 years, a period when the human brain is
still undergoing developmental changes. To increase
utility of the model, additional work is needed to char-
acterize the capacity of tumor cell lines to colonize
immature rodent brainstems. Other surgical approach-
es could be considered. The dorsal approach works
well for inoculations, but ventral approaches would be
superior for surgery in rodents and dogs.19
Conclusions
Tumor cells can be implanted in rat and mouse
brainstems to create laboratory models to investigate
new therapies for the treatment of brainstem lesions.
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